These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 15458455)

  • 1. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
    Linthorst GE; Hollak CE; Donker-Koopman WE; Strijland A; Aerts JM
    Kidney Int; 2004 Oct; 66(4):1589-95. PubMed ID: 15458455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
    Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
    CEN Case Rep; 2024 Aug; 13(4):290-296. PubMed ID: 38135868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.
    Vedder AC; Breunig F; Donker-Koopman WE; Mills K; Young E; Winchester B; Ten Berge IJ; Groener JE; Aerts JM; Wanner C; Hollak CE
    Mol Genet Metab; 2008 Jul; 94(3):319-25. PubMed ID: 18424138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
    Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
    Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
    J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.
    Ries M; Clarke JT; Whybra C; Mehta A; Loveday KS; Brady RO; Beck M; Schiffmann R
    J Clin Pharmacol; 2007 Oct; 47(10):1222-30. PubMed ID: 17698592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
    Ohashi T; Sakuma M; Kitagawa T; Suzuki K; Ishige N; Eto Y
    Mol Genet Metab; 2007 Nov; 92(3):271-3. PubMed ID: 17689998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
    Wilcox WR; Linthorst GE; Germain DP; Feldt-Rasmussen U; Waldek S; Richards SM; Beitner-Johnson D; Cizmarik M; Cole JA; Kingma W; Warnock DG
    Mol Genet Metab; 2012 Mar; 105(3):443-9. PubMed ID: 22227322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease.
    Limgala RP; Fikry J; Veligatla V; Goker-Alpan O
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.
    Mauhin W; Lidove O; Amelin D; Lamari F; Caillaud C; Mingozzi F; Dzangué-Tchoupou G; Arouche-Delaperche L; Douillard C; Dussol B; Leguy-Seguin V; D'Halluin P; Noel E; Zenone T; Matignon M; Maillot F; Ly KH; Besson G; Willems M; Labombarda F; Masseau A; Lavigne C; Froissart R; Lacombe D; Ziza JM; Hachulla E; Benveniste O
    Orphanet J Rare Dis; 2018 Jul; 13(1):127. PubMed ID: 30064518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment.
    van der Veen SJ; van Kuilenburg ABP; Hollak CEM; Kaijen PHP; Voorberg J; Langeveld M
    Mol Genet Metab; 2019 Feb; 126(2):162-168. PubMed ID: 30473480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
    Deegan PB
    J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
    Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
    Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson-Fabry disease.
    Stamerra CA; De Feo M; Castelli V; d'Angelo M; Cimini A; Grassi D; Ferri C
    Eur J Hum Genet; 2021 Feb; 29(2):218-224. PubMed ID: 32948848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
    Morimoto H; Ito Y; Yoden E; Horie M; Tanaka N; Komurasaki Y; Yamamoto R; Mihara K; Minami K; Hirato T
    Mol Genet Metab; 2018 Sep; 125(1-2):153-160. PubMed ID: 30054149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
    Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
    PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
    Ohashi T; Iizuka S; Ida H; Eto Y
    Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.